经导管主动脉瓣置换术中紧急植入补充瓣膜的发生率、原因与结局
基于国际注册研究21 298例TAVR的回顾性队列显示,2V-TAVR发生率为1.0%,2014至2018年从2.9%降至1.0%。瓣膜位置异常是主要原因,二叶式主动脉瓣、反流、非股动脉入路等增加风险。倾向评分匹配后,2V-TAVR组30天死亡率显著高于1V-TAVR组,但1年死亡率无显著差异。
要点
- 2V-TAVR发生率约1.0%,随时间下降,瓣膜位置异常是主要指征。
- 二叶式主动脉瓣、中度以上反流、非股动脉入路等增加2V-TAVR风险。
- 2V-TAVR与30天死亡率升高相关,但1年死亡率无显著差异。
核心结论
- 2V-TAVR总体发生率低且随时间下降,瓣膜位置异常是最常见原因。
- 二叶式主动脉瓣、中度以上主动脉瓣反流、心房颤动、非股动脉入路、早期瓣膜及自膨胀瓣膜与2V-TAVR风险升高相关。
- 匹配队列中2V-TAVR组30天死亡率显著高于1V-TAVR组,但1年死亡率差异无统计学意义。
研究设计与样本
- 回顾性队列研究,使用国际注册研究2014年1月1日至2019年2月28日期间21 298例TAVR手术数据。
- 共识别223例(1.0%)2V-TAVR患者;排除缺失30天随访或数据不一致后,纳入213例2V-TAVR和10 010例1V-TAVR患者。
- 采用1:4倾向评分匹配,最终分析纳入1065例患者(213例2V-TAVR vs 852例1V-TAVR)。
主要发现
- 2V-TAVR发生率从2014年的2.9%降至2018年的1.0%,在可重新定位瓣膜与非可重新定位瓣膜间相似。
- 在165例(80%)患者中,补充瓣膜植入的原因为初次瓣膜位置异常后残余主动脉瓣反流(94例[46.4%]位置过高,71例[34.2%]位置过低)。
关键数值与推荐
- 2V-TAVR发生率:2014年2.9%,2018年1.0%,总体1.0%(223/21 298)。
- 2V-TAVR指征:残余主动脉瓣反流后瓣膜位置异常(过高46.4%,过低34.2%)。
- 匹配队列中2V-TAVR组器械成功率70.4%,大出血率11.8%,瓣环破裂率3.3%。
临床怎么用
- TAVR术前应评估二叶式主动脉瓣、主动脉瓣反流、心房颤动及入路,识别2V-TAVR高风险患者。
- 术中应优化瓣膜定位,减少位置异常导致的残余反流和补充瓣膜植入。
- 发生2V-TAVR后需警惕30天内并发症和死亡风险升高,加强术后监护。
局限性
- 回顾性队列研究,存在选择偏倚和残留混杂可能。
- 仅56.6%的1V-TAVR患者有患者层面数据,可能影响对照组代表性。
- 部分患者因缺失30天随访或数据不一致被排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transcatheter aortic valve replacement (TAVR) failure is often managed by an urgent implantation of a supplementary valve during the procedure (2-valve TAVR [2V-TAVR]). Little is known about the factors associated with or sequelae of 2V-TAVR. OBJECTIVE: To examine the incidence, causes, and outcomes of 2V-TAVR. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was performed using data from an international registry of 21 298 TAVR procedures performed from January 1, 2014, through February 28, 2019. Among the 21 298 patients undergoing TAVR, 223 patients (1.0%) undergoing 2V-TAVR were identified. Patient-level data were available for all the patients undergoing 2V-TAVR and for 12 052 patients (56.6%) undergoing 1V-TAVR. After excluding patients with missing 30-day follow-up or data inconsistencies, 213 2V-TAVR and 10 010 1V-TAVR patients were studied. The 2V-TAVR patients were compared against control TAVR patients undergoing a 1-valve TAVR (1V-TAVR) using 1:4 17 propensity score matching. Final analysis included 1065 (213:852) patients. EXPOSURES: Urgent implantation of a supplementary valve during TAVR. MAIN OUTCOMES AND MEASURES: Mortality at 30 days and 1 year. RESULTS: The 213 patients undergoing 2V-TAVR had similar age (mean [SD], 81.3 [0.5] years) and sex (110 [51.6%] female) as the 10 010 patients undergoing 1V-TAVR (mean [SD] age, 81.2 [0.5] years; 110 [51.6%] female). The 2V-TAVR incidence decreased from 2.9% in 2014 to 1.0% in 2018 and was similar between repositionable and nonrepositionable valves. Bicuspid aortic valve (odds ratio [OR], 2.20; 95% CI, 1.17-4.15; P = .02), aortic regurgitation of moderate or greater severity (OR, 2.02; 95% CI, 1.49-2.73; P < .001), atrial fibrillation (OR, 1.43; 95% CI, 1.07-1.93; P = .02), alternative access (OR, 2.59; 95% CI, 1.72-3.89; P < .001), early-generation valve (OR, 2.32; 95% CI, 1.69-3.19; P < .001), and self-expandable valve (OR, 1.69; 95% CI, 1.17-2.43; P = .004) were associated with higher 2V-TAVR risk. In 165 patients (80%), the supplementary valve was implanted because of residual aortic regurgitation after primary valve malposition (94 [46.4%] too high and 71 [34.2%] too low). In the matched 2V-TAVR vs 1V-TAVR cohorts, the rate of device success was 147 (70.4%) vs 783 (92.2%) (P < .001), the rate of coronary obstruction was 5 (2.3%) vs 3 (0.4%) (P = .10), stroke rate was 9 (4.6%) vs 13 (1.6%) (P = .09), major bleeding rates were 25 (11.8%) vs 46 (5.5%) (P = .03) and annular rupture rate was 7 (3.3%) vs 3 (0.4%) (P = .03). The hazard ratios for mortality were 2.58 (95% CI, 1.04-6.45; P = .04) at 30 days, 1.45 (95% CI, 0.84-2.51; P = .18) at 1 year, and 1.20 (95% CI, 0.77-1.88; P = .42) at 2 years. Nontransfemoral access and certain periprocedural complications were independently associated with higher risk of death 1 year after 2V-TAVR. CONCLUSIONS AND RELEVANCE: In this cohort study, valve malposition was the most common indication for 2V-TAVR. Incidence decreased over time and was low overall, although patients with a bicuspid or regurgitant aortic valve, nontransfemoral access, and early-generation or self-expandable valve were at higher risk. These findings suggest that compared with 1V-TAVR, 2V-TAVR is associated with high burden of complications and mortality at 30 days but not at 1 year.
引用
- Landes U, Witberg G, Sathananthan J, et al. Incidence, Causes, and Outcomes Associated With Urgent Implantation of a Supplementary Valve During Transcatheter Aortic Valve Replacement. JAMA Cardiol. 2021. PMID: 34009236. doi:10.1001/jamacardio.2021.1145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。